Stem definition | Drug id | CAS RN |
---|---|---|
serotonin receptor antagonists (5-HT3) | 1329 | 109889-09-0 |
Dose | Unit | Route |
---|---|---|
2 | mg | O |
3 | mg | P |
3.10 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 100 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 11 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.03 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 3.70 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.35 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 5.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 29, 1993 | FDA | ROCHE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 392.94 | 17.20 | 308 | 17344 | 94319 | 46574091 |
Neutropenia | 183.08 | 17.20 | 247 | 17405 | 142957 | 46525453 |
Neutrophil count decreased | 155.77 | 17.20 | 130 | 17522 | 43296 | 46625114 |
Nausea | 155.04 | 17.20 | 588 | 17064 | 686866 | 45981544 |
Drug ineffective | 153.01 | 17.20 | 35 | 17617 | 677803 | 45990607 |
Pyrexia | 121.90 | 17.20 | 347 | 17305 | 348455 | 46319955 |
General physical health deterioration | 111.78 | 17.20 | 175 | 17477 | 115594 | 46552816 |
Vomiting | 106.19 | 17.20 | 393 | 17259 | 452401 | 46216009 |
Death | 103.05 | 17.20 | 319 | 17333 | 335229 | 46333181 |
Leukopenia | 99.75 | 17.20 | 126 | 17526 | 68217 | 46600193 |
Platelet count decreased | 86.67 | 17.20 | 144 | 17508 | 99880 | 46568530 |
White blood cell count decreased | 77.14 | 17.20 | 146 | 17506 | 112085 | 46556325 |
Decreased appetite | 67.58 | 17.20 | 193 | 17459 | 193643 | 46474767 |
Stomatitis | 65.49 | 17.20 | 103 | 17549 | 68194 | 46600216 |
Constipation | 58.39 | 17.20 | 171 | 17481 | 173926 | 46494484 |
Disease progression | 54.51 | 17.20 | 112 | 17540 | 91188 | 46577222 |
Diarrhoea | 53.13 | 17.20 | 377 | 17275 | 559225 | 46109185 |
Polyneuropathy | 52.71 | 17.20 | 40 | 17612 | 11604 | 46656806 |
Anaemia | 52.28 | 17.20 | 213 | 17439 | 255566 | 46412844 |
Tooth erosion | 47.05 | 17.20 | 14 | 17638 | 465 | 46667945 |
Thrombocytopenia | 45.96 | 17.20 | 128 | 17524 | 126453 | 46541957 |
Pancytopenia | 45.74 | 17.20 | 100 | 17552 | 84958 | 46583452 |
Joint swelling | 45.24 | 17.20 | 5 | 17647 | 166068 | 46502342 |
Completed suicide | 43.51 | 17.20 | 3 | 17649 | 145917 | 46522493 |
Drug hypersensitivity | 43.33 | 17.20 | 19 | 17633 | 243806 | 46424604 |
Malignant neoplasm progression | 41.54 | 17.20 | 82 | 17570 | 64844 | 46603566 |
Product dose omission issue | 39.21 | 17.20 | 8 | 17644 | 168512 | 46499898 |
Mucosal inflammation | 37.64 | 17.20 | 59 | 17593 | 38917 | 46629493 |
Fall | 37.01 | 17.20 | 42 | 17610 | 329055 | 46339355 |
Toxicity to various agents | 36.84 | 17.20 | 17 | 17635 | 211749 | 46456661 |
Dyspnoea | 36.55 | 17.20 | 325 | 17327 | 515223 | 46153187 |
Condition aggravated | 36.37 | 17.20 | 24 | 17628 | 245028 | 46423382 |
Pulpitis dental | 36.24 | 17.20 | 13 | 17639 | 784 | 46667626 |
Bone marrow failure | 34.50 | 17.20 | 49 | 17603 | 29620 | 46638790 |
Ileus | 34.42 | 17.20 | 34 | 17618 | 14030 | 46654380 |
Palmar-plantar erythrodysaesthesia syndrome | 31.87 | 17.20 | 39 | 17613 | 20412 | 46647998 |
Cytomegalovirus test positive | 31.15 | 17.20 | 17 | 17635 | 2803 | 46665607 |
Weight increased | 30.52 | 17.20 | 12 | 17640 | 164461 | 46503949 |
Periodontitis | 30.43 | 17.20 | 18 | 17634 | 3458 | 46664952 |
Respiratory depth decreased | 29.35 | 17.20 | 6 | 17646 | 38 | 46668372 |
Metastases to liver | 28.36 | 17.20 | 36 | 17616 | 19549 | 46648861 |
Breast cancer metastatic | 27.93 | 17.20 | 30 | 17622 | 13648 | 46654762 |
Erythema | 27.58 | 17.20 | 117 | 17535 | 142703 | 46525707 |
Lymphoedema | 27.21 | 17.20 | 24 | 17628 | 8588 | 46659822 |
Drug intolerance | 26.83 | 17.20 | 11 | 17641 | 147038 | 46521372 |
Acute myeloid leukaemia recurrent | 26.02 | 17.20 | 12 | 17640 | 1384 | 46667026 |
Venous thrombosis limb | 25.52 | 17.20 | 15 | 17637 | 2848 | 46665562 |
Sepsis | 25.16 | 17.20 | 110 | 17542 | 135904 | 46532506 |
Flushing | 25.08 | 17.20 | 67 | 17585 | 64547 | 46603863 |
Lymphocyte count decreased | 25.07 | 17.20 | 39 | 17613 | 25550 | 46642860 |
Acute graft versus host disease in skin | 24.95 | 17.20 | 15 | 17637 | 2967 | 46665443 |
Off label use | 23.59 | 17.20 | 233 | 17419 | 379608 | 46288802 |
Abdominal pain | 23.44 | 17.20 | 158 | 17494 | 229873 | 46438537 |
Chronic hepatitis B | 23.09 | 17.20 | 7 | 17645 | 248 | 46668162 |
Interstitial lung disease | 23.05 | 17.20 | 58 | 17594 | 53891 | 46614519 |
Neuropathy peripheral | 22.88 | 17.20 | 81 | 17571 | 90812 | 46577598 |
Hepatic function abnormal | 22.64 | 17.20 | 44 | 17608 | 34377 | 46634033 |
Treatment failure | 22.53 | 17.20 | 4 | 17648 | 93083 | 46575327 |
Subileus | 22.31 | 17.20 | 14 | 17638 | 2989 | 46665421 |
Arthropathy | 21.95 | 17.20 | 3 | 17649 | 84697 | 46583713 |
Arthralgia | 21.94 | 17.20 | 68 | 17584 | 364535 | 46303875 |
Bone pain | 21.72 | 17.20 | 52 | 17600 | 46838 | 46621572 |
Disseminated intravascular coagulation | 21.52 | 17.20 | 31 | 17621 | 18974 | 46649436 |
Mitral valve disease | 20.80 | 17.20 | 12 | 17640 | 2200 | 46666210 |
Mucosal dryness | 20.42 | 17.20 | 12 | 17640 | 2278 | 46666132 |
Musculoskeletal stiffness | 20.16 | 17.20 | 6 | 17646 | 97987 | 46570423 |
Hypokalaemia | 20.09 | 17.20 | 76 | 17576 | 87948 | 46580462 |
Anaphylactic shock | 20.00 | 17.20 | 31 | 17621 | 20243 | 46648167 |
Chest discomfort | 19.83 | 17.20 | 77 | 17575 | 90192 | 46578218 |
Maternal exposure during pregnancy | 19.82 | 17.20 | 7 | 17645 | 102542 | 46565868 |
Mucosal disorder | 19.72 | 17.20 | 11 | 17641 | 1893 | 46666517 |
Therapeutic product effect incomplete | 19.71 | 17.20 | 3 | 17649 | 78150 | 46590260 |
Acute interstitial pneumonitis | 19.65 | 17.20 | 8 | 17644 | 682 | 46667728 |
Cytopenia | 19.42 | 17.20 | 19 | 17633 | 7749 | 46660661 |
Pseudomembranous colitis | 19.10 | 17.20 | 13 | 17639 | 3182 | 46665228 |
Peripheral swelling | 19.04 | 17.20 | 19 | 17633 | 158052 | 46510358 |
Sinusitis | 18.84 | 17.20 | 13 | 17639 | 129755 | 46538655 |
Tumour lysis syndrome | 18.65 | 17.20 | 18 | 17634 | 7218 | 46661192 |
Pleural effusion | 18.42 | 17.20 | 71 | 17581 | 82881 | 46585529 |
Exposure during pregnancy | 18.32 | 17.20 | 9 | 17643 | 108203 | 46560207 |
Fatigue | 17.92 | 17.20 | 326 | 17326 | 608371 | 46060039 |
Allergy to chemicals | 17.89 | 17.20 | 8 | 17644 | 859 | 46667551 |
Oral candidiasis | 17.56 | 17.20 | 27 | 17625 | 17505 | 46650905 |
Ascites | 17.40 | 17.20 | 41 | 17611 | 36543 | 46631867 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 268.10 | 16.59 | 287 | 13659 | 106406 | 29832126 |
Neutrophil count decreased | 127.56 | 16.59 | 126 | 13820 | 42328 | 29896204 |
White blood cell count decreased | 88.57 | 16.59 | 148 | 13798 | 83799 | 29854733 |
Drug ineffective | 87.96 | 16.59 | 25 | 13921 | 340362 | 29598170 |
Pyrexia | 81.92 | 16.59 | 311 | 13635 | 294178 | 29644354 |
Leukopenia | 71.57 | 16.59 | 108 | 13838 | 56051 | 29882481 |
Platelet count decreased | 70.86 | 16.59 | 154 | 13792 | 105975 | 29832557 |
Neutropenia | 62.58 | 16.59 | 165 | 13781 | 128375 | 29810157 |
Vomiting | 57.54 | 16.59 | 228 | 13718 | 219590 | 29718942 |
Stomatitis | 56.70 | 16.59 | 78 | 13868 | 37201 | 29901331 |
Nausea | 52.34 | 16.59 | 274 | 13672 | 296683 | 29641849 |
Mucosal disorder | 50.30 | 16.59 | 21 | 13925 | 1546 | 29936986 |
Decreased appetite | 42.82 | 16.59 | 160 | 13786 | 149750 | 29788782 |
Interstitial lung disease | 42.00 | 16.59 | 89 | 13857 | 60108 | 29878424 |
Disseminated intravascular coagulation | 40.85 | 16.59 | 51 | 13895 | 22120 | 29916412 |
Sepsis | 40.77 | 16.59 | 155 | 13791 | 146240 | 29792292 |
Diarrhoea | 38.34 | 16.59 | 276 | 13670 | 333827 | 29604705 |
Thrombocytopenia | 35.62 | 16.59 | 142 | 13804 | 136902 | 29801630 |
Polyneuropathy | 35.28 | 16.59 | 35 | 13911 | 11788 | 29926744 |
Fall | 34.55 | 16.59 | 21 | 13925 | 181851 | 29756681 |
Antithrombin III decreased | 34.22 | 16.59 | 11 | 13935 | 383 | 29938149 |
Colorectal cancer | 32.21 | 16.59 | 16 | 13930 | 1763 | 29936769 |
General physical health deterioration | 29.60 | 16.59 | 108 | 13838 | 99836 | 29838696 |
Constipation | 29.32 | 16.59 | 117 | 13829 | 112789 | 29825743 |
C-reactive protein increased | 28.84 | 16.59 | 63 | 13883 | 43410 | 29895122 |
Disease progression | 28.63 | 16.59 | 92 | 13854 | 79782 | 29858750 |
Dermatitis acneiform | 27.24 | 16.59 | 22 | 13924 | 5667 | 29932865 |
Product dose omission issue | 27.00 | 16.59 | 5 | 13941 | 91626 | 29846906 |
Blast cell count increased | 26.91 | 16.59 | 12 | 13934 | 1037 | 29937495 |
Hiccups | 26.44 | 16.59 | 27 | 13919 | 9407 | 29929125 |
Drug therapeutic incompatibility | 25.95 | 16.59 | 7 | 13939 | 130 | 29938402 |
Tumour perforation | 24.98 | 16.59 | 8 | 13938 | 275 | 29938257 |
Acute graft versus host disease in skin | 24.94 | 16.59 | 19 | 13927 | 4497 | 29934035 |
Anaemia | 23.85 | 16.59 | 172 | 13774 | 207820 | 29730712 |
Lymphocyte count decreased | 23.32 | 16.59 | 36 | 13910 | 19019 | 29919513 |
Enterocolitis | 22.21 | 16.59 | 21 | 13925 | 6666 | 29931866 |
Myocardial infarction | 21.82 | 16.59 | 16 | 13930 | 125609 | 29812923 |
Hepatic function abnormal | 21.52 | 16.59 | 55 | 13891 | 41890 | 29896642 |
Off label use | 21.42 | 16.59 | 193 | 13753 | 249097 | 29689435 |
Non-small cell lung cancer | 21.27 | 16.59 | 16 | 13930 | 3714 | 29934818 |
Toxicity to various agents | 21.25 | 16.59 | 31 | 13915 | 177152 | 29761380 |
Pneumonia | 21.17 | 16.59 | 243 | 13703 | 334063 | 29604469 |
Mucosal inflammation | 21.14 | 16.59 | 45 | 13901 | 30449 | 29908083 |
Laryngeal leukoplakia | 20.97 | 16.59 | 5 | 13941 | 55 | 29938477 |
Dehydration | 20.94 | 16.59 | 113 | 13833 | 123426 | 29815106 |
Peripheral sensory neuropathy | 20.50 | 16.59 | 19 | 13927 | 5882 | 29932650 |
Ileus | 19.90 | 16.59 | 30 | 13916 | 15525 | 29923007 |
Engraftment syndrome | 19.69 | 16.59 | 9 | 13937 | 824 | 29937708 |
Nail bed inflammation | 19.58 | 16.59 | 6 | 13940 | 178 | 29938354 |
Palmar-plantar erythrodysaesthesia syndrome | 19.48 | 16.59 | 29 | 13917 | 14841 | 29923691 |
Fluid imbalance | 18.78 | 16.59 | 7 | 13939 | 381 | 29938151 |
Pulpitis dental | 18.47 | 16.59 | 7 | 13939 | 399 | 29938133 |
Arthralgia | 18.06 | 16.59 | 22 | 13924 | 135769 | 29802763 |
Hypoalbuminaemia | 18.05 | 16.59 | 24 | 13922 | 11068 | 29927464 |
Proteinuria | 17.69 | 16.59 | 29 | 13917 | 16116 | 29922416 |
Ileal perforation | 17.54 | 16.59 | 8 | 13938 | 729 | 29937803 |
Blood lactate dehydrogenase increased | 17.39 | 16.59 | 33 | 13913 | 20568 | 29917964 |
Bone marrow failure | 17.34 | 16.59 | 41 | 13905 | 29744 | 29908788 |
Cardiac failure congestive | 17.07 | 16.59 | 9 | 13937 | 84398 | 29854134 |
Source | Code | Description |
---|---|---|
ATC | A04AA02 | ALIMENTARY TRACT AND METABOLISM ANTIEMETICS AND ANTINAUSEANTS ANTIEMETICS AND ANTINAUSEANTS Serotonin (5HT3) antagonists |
FDA MoA | N0000175817 | Serotonin 3 Receptor Antagonists |
FDA EPC | N0000175818 | Serotonin-3 Receptor Antagonist |
CHEBI has role | CHEBI:48279 | serotonin antagonists |
CHEBI has role | CHEBI:50919 | antiemetico |
MeSH PA | D000932 | Antiemetics |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D005765 | Gastrointestinal Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D012702 | Serotonin Antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Post-Operative Nausea and Vomiting | indication | 1488000 | |
Chemotherapy-induced nausea and vomiting | indication | 236084000 | |
Prevention of Post-Operative Nausea and Vomiting | indication | ||
Prevention of Radiation-Induced Nausea and Vomiting | indication | ||
Prolonged-Severe Nausea and Vomiting | off-label use | ||
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Prolonged QT interval | contraindication | 111975006 | |
Hypomagnesemia | contraindication | 190855004 | |
Congenital long QT syndrome | contraindication | 442917000 | |
Doxorubicin Induced Cardiomyopathy | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.79 | acidic |
pKa2 | 9.5 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3A | Ion channel | ANTAGONIST | Ki | 8.70 | WOMBAT-PK | CHEMBL | |||
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 4.42 | CHEMBL | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 5.37 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | Ki | 4.17 | CHEMBL | |||||
5-hydroxytryptamine receptor 3B | Ion channel | Ki | 8.80 | CHEMBL | |||||
Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.30 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.43 | WOMBAT-PK | |||||
Serotonin 3 (5-HT3) receptor | Ion channel | Ki | 9.46 | CHEMBL |
ID | Source |
---|---|
4020855 | VUID |
N0000179527 | NUI |
D00677 | KEGG_DRUG |
107007-99-8 | SECONDARY_CAS_RN |
4020855 | VANDF |
4023910 | VANDF |
C0733443 | UMLSCUI |
CHEBI:5537 | CHEBI |
CWB | PDB_CHEM_ID |
CHEMBL289469 | ChEMBL_ID |
CHEMBL1237080 | ChEMBL_ID |
DB00889 | DRUGBANK_ID |
D017829 | MESH_DESCRIPTOR_UI |
5284566 | PUBCHEM_CID |
2300 | IUPHAR_LIGAND_ID |
6230 | INN_ID |
WZG3J2MCOL | UNII |
142149 | RXNORM |
130105 | MMSL |
157872 | MMSL |
25895 | MMSL |
4801 | MMSL |
d03171 | MMSL |
003975 | NDDF |
003976 | NDDF |
108424001 | SNOMEDCT_US |
108425000 | SNOMEDCT_US |
372489005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0143 | TABLET | 1 mg | ORAL | ANDA | 19 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9744 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9745 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-221 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 20 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-221 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 20 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-546 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 26 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-547 | INJECTION | 0.10 mg | INTRAVENOUS | ANDA | 26 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42043-390 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 20 sections |
SANCUSO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42747-726 | PATCH | 3.10 mg | TRANSDERMAL | NDA | 31 sections |
SUSTOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47426-101 | INJECTION | 10 mg | SUBCUTANEOUS | NDA | 27 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-735 | TABLET | 1 mg | ORAL | ANDA | 21 sections |
Sancuso | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5985 | PATCH | 3.10 mg | TRANSDERMAL | NDA | 26 sections |
Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 55150-175 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 55150-176 | INJECTION, SOLUTION | 4 mg | INTRAVENOUS | ANDA | 24 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-661 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-661 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 16 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55648-662 | INJECTION | 0.10 mg | INTRAVENOUS | ANDA | 16 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63126-331 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | ANDA | 26 sections |
Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-317 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | ANDA | 25 sections |
Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-318 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Granisetron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-319 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 25 sections |
Granisetron hydrochloride | Human Prescription Drug Label | 1 | 63850-0005 | TABLET, FILM COATED | 1 mg | ORAL | ANDA | 18 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-661 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-662 | INJECTION | 0.10 mg | INTRAVENOUS | ANDA | 23 sections |
GRANISETRON HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-841 | INJECTION | 1 mg | INTRAVENOUS | ANDA | 23 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-861 | INJECTION, SOLUTION | 0.10 mg | INTRAVENOUS | ANDA | 24 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-863 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
Granisetron Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67457-864 | INJECTION, SOLUTION | 1 mg | INTRAVENOUS | ANDA | 24 sections |
Granisetron Hydrochloride | Human Prescription Drug Label | 1 | 67877-184 | TABLET | 1 mg | ORAL | ANDA | 16 sections |